Press Release

Cipla announces Q1 FY 1314 Unaudited Financial Results

Mumbai, India, 9th August 2013: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its Unaudited Financial Results for the quarter ended June 30, 2013 (Q1).

Key Financial & Performance Highlights Q1 FY1314 vis-a-vis Q1 FY1213:

- Gross revenues grew by 25.3% to ₹2492 cr, up from ₹1989 cr
- Operating margins grew by 24.8% to ₹675 cr, up from ₹541 cr
- Profit after tax grew by 18.5% to ₹475 cr, up from ₹401 cr
Profit & Loss Highlights:

- Material cost is at 40.8% of Total Sales in Q1 FY1314 as compared to 37.6% in Q1 FY1213.
- Operating margins increased by 24.8% and is at 27.1% of Income from Operations during Q1 FY1314.
- Profit after tax increased by 18.5% to ₹475 cr during Q1 FY1314 as compared to ₹401 cr during Q1 FY1213.

Performance Review:

Domestic business:

- Domestic revenues grew by 16.7% to ₹1132 cr during Q1 FY1314, up from ₹970 cr during Q1 FY1213.
- The growth in domestic revenues was largely on account of growth in anti-asthma, anti-biotics/infectives, and cardiovascular therapy segments.

International business:

- Exports of formulations grew by 27.7% to ₹1034 cr during Q1 FY1314, up from ₹810 cr during Q1 FY1213.
- Exports of APIs fell by 13.1% to ₹146 cr during Q1 FY1314, from ₹168 cr during Q1 FY1213.
- The growth in export revenues was primarily due to growth in anti-retroviral, anti-asthma and anti-allergic segments.

About Cipla:
Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US$ 1.5 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. ([www.cipla.com](http://www.cipla.com)).

Media Contact:

<table>
<thead>
<tr>
<th>Finance</th>
<th>Corporate Communications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ajay Luharuka</td>
<td>Jaisingh Balakrishnan</td>
</tr>
<tr>
<td>Contact No.: 022 – 23025435</td>
<td>Contact No.: 022 - 23025813</td>
</tr>
<tr>
<td>E-Mail: <a href="mailto:ajay@cipla.com">ajay@cipla.com</a></td>
<td>E Mail: <a href="mailto:jaisingh.krishnan@cipla.com">jaisingh.krishnan@cipla.com</a></td>
</tr>
</tbody>
</table>